MDGL — Madrigal Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $5.25bn
- $4.31bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 95 | 207 | 242 | 294 | 380 |
Operating Profit | -95 | -207 | -242 | -294 | -380 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -83.9 | -202 | -242 | -295 | -374 |
Provision for Income Taxes | |||||
Net Income After Taxes | -83.9 | -202 | -242 | -295 | -374 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -83.9 | -202 | -242 | -295 | -374 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -83.9 | -202 | -242 | -295 | -374 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -5.45 | -13.1 | -14.6 | -17.2 | -20 |